Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies

Jefferies analyst Kelly Shi lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $64.00 (from $66.00) while maintaining a Buy rating.

The analyst comments "KYMR announced two updates on parternship: 1) SNY will not advance Ph2 IRAK4 degrader KT-474 in AD/HS and will prioritize next-gen degrader KT-485, with Ph1 expected to initiate in 2026; 2) To develop CDK2 molecular glues w/ GILD, which has pot'l to unlock >$5B oppy in breast/ovarian cancers. Following positive FIH data (note), the lead program STAT6 degrader KT-621 has Ph1b AD data (Q4'25) in focus, which could further illuminate its pot'l as "oral Dupixent"."

You May Also Be Interested In

• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• Wells Fargo Upgrades FOX Corp. (FOXA) to Overweight
• Workday (WDAY) PT Raised to $220 at UBS